Steve S Cho1,2, Saad Sheikh3, Clare W Teng1,2, Joseph Georges4,5, Andrew I Yang1, Emma De Ravin1,2, Love Buch1, Carrie Li1,2, Yash Singh1, Denah Appelt4, Edward J Delikatny6, E James Petersson7, Andrew Tsourkas8, Jay Dorsey3, Sunil Singhal9, John Y K Lee10. 1. Department of Neurosurgery, Hospital of the University of Pennsylvania, Philadelphia, PA, USA. 2. Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA. 3. Department of Radiation Oncology, Hospital of the University of Pennsylvania, Philadelphia, PA, USA. 4. Department of Biomedical Sciences, Philadelphia College of Osteopathic Medicine, Philadelphia, PA, USA. 5. Department of Neurosurgery, Philadelphia College of Osteopathic Medicine, Philadelphia, PA, USA. 6. Department of Radiology, University of Pennsylvania, Philadelphia, PA, USA. 7. Department of Chemistry, University of Pennsylvania, Philadelphia, PA, USA. 8. Department of Bioengineering, University of Pennsylvania, Philadelphia, PA, USA. 9. Department of Surgery, Hospital of the University of Pennsylvania, Philadelphia, PA, USA. 10. Department of Neurosurgery, Hospital of the University of Pennsylvania, Philadelphia, PA, USA. leejohn@uphs.upenn.edu.
Abstract
PURPOSE: Fluorescence-guided-surgery offers intraoperative visualization of neoplastic tissue. Delta-aminolevulinic acid (5-ALA), which targets enzymatic abnormality in neoplastic cells, is the only approved agent for fluorescence-guided neurosurgery. More recently, we described Second Window Indocyanine Green (SWIG) which targets neoplastic tissue through enhanced vascular permeability. We hypothesized that SWIG would demonstrate similar clinical utility in identification of high-grade gliomas compared with 5-ALA. PROCEDURES: Female C57/BL6 and nude/athymic mice underwent intracranial implantation of 300,000 GL261 and U87 cells, respectively. Tumor-bearing mice were euthanized after administration of 5-ALA (200 mg/kg intraperitoneal) and SWIG (5 mg/kg intravenous). Brain sections were imaged for protoporphyrin-IX and ICG fluorescence. Fluorescence and H&E images were registered using semi-automatic scripts for analysis. Human subjects with HGG were administered SWIG (2.5 mg/kg intravenous) and 5-ALA (20 mg/kg oral). Intraoperatively, tumors were imaged for ICG and protoporphyrin-IX fluorescence. RESULTS: In non-necrotic tumors, 5-ALA and SWIG demonstrated 90.2 % and 89.2 % tumor accuracy (p value = 0.52) in U87 tumors and 88.1 % and 87.7 % accuracy (p value = 0.83) in GL261 tumors. The most distinct difference between 5-ALA and SWIG distribution was seen in areas of tumor-associated necrosis, which often showed weak/no protoporphyrin-IX fluorescence, but strong SWIG fluorescence. In twenty biopsy specimens from four subjects with HGG, SWIG demonstrated 100 % accuracy, while 5-ALA demonstrated 75-85 % accuracy; there was 90 % concordance between SWIG and 5-ALA fluorescence. CONCLUSION: Our results provide the first direct comparison of the diagnostic utility of SWIG vs 5-ALA in both rodent and human HGG. Given the broader clinical utility of SWIG compared with 5-ALA, our data supports the use of SWIG in tumor surgery to improve the extent of safe resections. CLINICAL TRIAL: NCT02710240 (US National Library of Medicine Registry; https://www.clinicaltrials.gov/ct2/show/NCT02710240?id=NCT02710240&draw=2&rank=1 ).
PURPOSE: Fluorescence-guided-surgery offers intraoperative visualization of neoplastic tissue. Delta-aminolevulinic acid (5-ALA), which targets enzymatic abnormality in neoplastic cells, is the only approved agent for fluorescence-guided neurosurgery. More recently, we described Second Window Indocyanine Green (SWIG) which targets neoplastic tissue through enhanced vascular permeability. We hypothesized that SWIG would demonstrate similar clinical utility in identification of high-grade gliomas compared with 5-ALA. PROCEDURES: Female C57/BL6 and nude/athymic mice underwent intracranial implantation of 300,000 GL261 and U87 cells, respectively. Tumor-bearing mice were euthanized after administration of 5-ALA (200 mg/kg intraperitoneal) and SWIG (5 mg/kg intravenous). Brain sections were imaged for protoporphyrin-IX and ICG fluorescence. Fluorescence and H&E images were registered using semi-automatic scripts for analysis. Human subjects with HGG were administered SWIG (2.5 mg/kg intravenous) and 5-ALA (20 mg/kg oral). Intraoperatively, tumors were imaged for ICG and protoporphyrin-IX fluorescence. RESULTS: In non-necrotic tumors, 5-ALA and SWIG demonstrated 90.2 % and 89.2 % tumor accuracy (p value = 0.52) in U87tumors and 88.1 % and 87.7 % accuracy (p value = 0.83) in GL261tumors. The most distinct difference between 5-ALA and SWIG distribution was seen in areas of tumor-associated necrosis, which often showed weak/no protoporphyrin-IX fluorescence, but strong SWIG fluorescence. In twenty biopsy specimens from four subjects with HGG, SWIG demonstrated 100 % accuracy, while 5-ALA demonstrated 75-85 % accuracy; there was 90 % concordance between SWIG and 5-ALA fluorescence. CONCLUSION: Our results provide the first direct comparison of the diagnostic utility of SWIG vs 5-ALA in both rodent and human HGG. Given the broader clinical utility of SWIG compared with 5-ALA, our data supports the use of SWIG in tumor surgery to improve the extent of safe resections. CLINICAL TRIAL: NCT02710240 (US National Library of Medicine Registry; https://www.clinicaltrials.gov/ct2/show/NCT02710240?id=NCT02710240&draw=2&rank=1 ).
Entities:
Keywords:
5-ALA; Fluorescence-guided surgery; High grade glioma; Near-infrared; Second-window ICG
Authors: John S Kuo; Garni Barkhoudarian; Christopher J Farrell; Mary E Bodach; Luis M Tumialan; Nelson M Oyesiku; Zachary Litvack; Gabriel Zada; Chirag G Patil; Manish K Aghi Journal: Neurosurgery Date: 2016-10 Impact factor: 4.654
Authors: W Stummer; S Stocker; S Wagner; H Stepp; C Fritsch; C Goetz; A E Goetz; R Kiefmann; H J Reulen Journal: Neurosurgery Date: 1998-03 Impact factor: 4.654
Authors: C R Wirtz; F K Albert; M Schwaderer; C Heuer; A Staubert; V M Tronnier; M Knauth; S Kunze Journal: Neurol Res Date: 2000-06 Impact factor: 2.448
Authors: M Lacroix; D Abi-Said; D R Fourney; Z L Gokaslan; W Shi; F DeMonte; F F Lang; I E McCutcheon; S J Hassenbusch; E Holland; K Hess; C Michael; D Miller; R Sawaya Journal: J Neurosurg Date: 2001-08 Impact factor: 5.115
Authors: Jan Coburger; Jens Engelke; Angelika Scheuerle; Dietmar R Thal; Michal Hlavac; Christian Rainer Wirtz; Ralph König Journal: Neurosurg Focus Date: 2014-02 Impact factor: 4.047